PC1575
(Plasmid
#232088)
-
PurposeMammalian expression plasmid for ubiquibody (uAb) cloning backbone. Includes an Esp3I restriction site directly upstream of GSGSG linker and CHIPΔTPR CDS and a C-terminal IRES-mCherry cassette.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 232088 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3
- Backbone size w/o insert (bp) 5400
- Total vector size (bp) 7285
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameuAb with cloning Esp3I restriction site
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1899
- Promoter CMV
-
Tag
/ Fusion Protein
- IRES-mCherry (N terminal on insert)
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer CMV-Forward (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please visit https://doi.org/10.1101/2023.06.26.546591 for bioRxiv preprint.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
PC1575 was a gift from Pranam Chatterjee (Addgene plasmid # 232088 ; http://n2t.net/addgene:232088 ; RRID:Addgene_232088) -
For your References section:
De Novo Design of Peptide Binders to Conformationally Diverse Targets with Contrastive Language Modeling. Bhat S, Palepu K, Hong L, Mao J, Ye T, Iyer R, Zhao L, Chen T, Vincoff S, Watson R, Wang T, Srijay D, Kavirayuni VS, Kholina K, Goel S, Vure P, Desphande AJ, Soderling SH, DeLisa MP, Chatterjee P. Science Advances, 22 Jan 2025. Vol 11, Issue 4. DOI: 10.1126/sciadv.adr8638 10.1101/2023.06.26.546591 PubMed 39091799